| Open Document File Size: 2,62 MBShare Result on Facebook
City Reference / / Company Concordia Pharmaceuticals Inc. / / Country United States / / Currency USD / / Event FDA Phase / Product Issues / Product Recall / / Facility Laboratory Findings / / IndustryTerm injection solution / treatment of attention deficit hyperactivity disorder / methylphenidate product / age / amphetamine product / treatment of hypertension / delivery systems / / MedicalCondition ADHD / hypertension / cancer / sinus node dysfunction / marketed/hypertension / hypotension/bradycardia / attention deficit hyperactivity disorder / chronic nature / withdrawal syndrome / / MedicalTreatment adjunctive therapy / / Organization office of Scientific Investigations / PDUFA Goal Date Division / FDA / MD NDA / / Person Review Roberta Glass / John McCleery / Roberta Glass / / Position investigator / listed investigator / speaker / single investigator / site investigator / Director Financial Disclosures The Managing / / Product Wellbutrin / Overdose / Methylin / Clonidine hydrochloride / Chewable Tablets / Desoxyn / Duraclon / Concerta / syndrome / Focalin / Adderall / Vyvanse / Tofranil / Norpramin / Pamelor / Daytrana / Strattera / Elavil / Tenex / study / Ritalin / Strattera® (atomoxetine) Capsules / Kapvay / Kapvay® / Jenloga / / Technology Alpha / Pharmacokinetics / Pharmacodynamics / /
SocialTag |
N22-331S014 Clonidine Clinical PREA